Zoetis Inc. is a global producer of medicine and vaccinations for pets and livestock, operating a comprehensive animal health business model. The company discovers, develops, manufactures, and commercializes a wide range of veterinary products, including vaccines, parasiticides, anti-infectives, dermatology therapeutics, and medicated feed additives. Zoetis also provides portable blood and urine analysis testing, point-of-care diagnostic instruments, and reference laboratory services.
The company organizes its commercial operations into two geographic segments: the United States and International. The U.S. segment accounts for approximately 54% of total revenue, while the International segment contributes roughly 45%. Across these regions, Zoetis categorizes its revenue by species into companion animals (dogs, cats, and horses) and livestock (cattle, swine, poultry, fish, and sheep). Companion animal products represent approximately 68% of total revenue, driven by demand for treatments such as monoclonal antibodies for osteoarthritis pain, dermatology products, and combination parasiticides. Livestock products account for the remaining 31% of revenue, providing vaccines and anti-infectives to global food producers.
Zoetis markets its products directly to veterinarians, livestock producers, and retail outlets, as well as through third-party veterinary distributors. With a presence in over 100 countries and a dedicated research and development pipeline, the company maintains a prominent competitive position in the global animal health industry. Its business benefits from long-term trends such as the increasing medicalization of pets and the rising global demand for animal protein.
